APA
Bernot K. M., Siebenaler R. F., Whitman S. P., Zorko N. A., Marcucci G. G., Santhanam R., Ahmed E. H., Ngangana M., McConnell K. K., Nemer J. S., Brook D. L., Kulp S. K., Chen C. S., Frankhouser D., Yan P., Bundschuh R., Zhang X., Dorrance A. M., Dickerson K. E., Jarjoura D., Blum W., Marcucci G. & Caligiuri M. A. (20140310). Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML. : Leukemia.
Chicago
Bernot K M, Siebenaler R F, Whitman S P, Zorko N A, Marcucci G G, Santhanam R, Ahmed E H, Ngangana M, McConnell K K, Nemer J S, Brook D L, Kulp S K, Chen C S, Frankhouser D, Yan P, Bundschuh R, Zhang X, Dorrance A M, Dickerson K E, Jarjoura D, Blum W, Marcucci G and Caligiuri M A. 20140310. Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML. : Leukemia.
Harvard
Bernot K. M., Siebenaler R. F., Whitman S. P., Zorko N. A., Marcucci G. G., Santhanam R., Ahmed E. H., Ngangana M., McConnell K. K., Nemer J. S., Brook D. L., Kulp S. K., Chen C. S., Frankhouser D., Yan P., Bundschuh R., Zhang X., Dorrance A. M., Dickerson K. E., Jarjoura D., Blum W., Marcucci G. and Caligiuri M. A. (20140310). Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML. : Leukemia.
MLA
Bernot K M, Siebenaler R F, Whitman S P, Zorko N A, Marcucci G G, Santhanam R, Ahmed E H, Ngangana M, McConnell K K, Nemer J S, Brook D L, Kulp S K, Chen C S, Frankhouser D, Yan P, Bundschuh R, Zhang X, Dorrance A M, Dickerson K E, Jarjoura D, Blum W, Marcucci G and Caligiuri M A. Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML. : Leukemia. 20140310.